Oncology Data Advisor public
[search 0]
More

Download the App!

show episodes
 
Loading …
show series
 
To claim CME credit, visit https://i3health.com/oda-nsclc-krasOne of the two major subtypes of lung cancer, non-small cell lung cancer (NSCLC) is a challenging disease to treat, with most patients being diagnosed at a locally advanced or metastatic stage. Despite the use of tumor histology and relevant molecular biomarkers to determine treatment st…
 
To claim CME credit, visit https://i3health.com/burnout-in-oncologyPhysician burnout and work-related stress are serious and prevalent issues in oncology, with nearly 45% of oncologists experiencing signs of burnout. Recently, this problem has been further exacerbated by the challenges brought about by the COVID-19 pandemic. In this episode of Onco…
 
To claim CME/NCPD credit for this podcast, visit i3health.com/advanced-merkel-cell-carcinomaIn this bonus episode of Oncology Data Advisor, learn more about emerging evidence on immunotherapeutic strategies for advanced MCC and multidisciplinary approaches to monitor and manage immune-related adverse events in patients with advanced MCC in this act…
 
To claim CME/NCPD credit for this podcast, visit i3health.com/oda-renal-cell-carcinomaKidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is character…
 
To claim CME/NCPD credit for this podcast, visit https://i3health.com/oda-nsclcOne of the two major subtypes of lung cancer, non-small cell lung cancer (NSCLC) is a challenging disease to treat, with most patients being diagnosed at a locally advanced or metastatic stage. Despite the use of tumor histology and relevant molecular biomarkers to deter…
 
To claim CME/MOC credit for this podcast, visit https://i3health.com/oda-cholangiocarcinomaWith an estimated incidence of 8,000 new cases per year, cholangiocarcinoma is a rare and aggressive tumor type that accounts for only 3% of all gastrointestinal cancers. Outcomes are poor, with 5-year survival rates ranging from 24% to as low as 2%. In this …
 
To claim CME credit for this podcast, visit https://i3health.com/oda-mclAn aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncol…
 
To claim CME credit for this podcast, visit https://i3health.com/oda-pancreaticWith 5-year survival rates of only 37% for local disease, 12% for regional disease, and 3% for distant disease, pancreatic cancer is one of the most aggressive forms of cancer and one of the most challenging to treat. Despite the development of novel treatment approaches…
 
To claim CME/NCPD credit for this podcast, visit i3Health.com/GISTThe fact that gastrointestinal stromal tumor (GIST) is a rare tumor type, with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest the…
 
Oncology Data Advisor welcomes back Carol Viele, RN, MS, OCN®, CNS, a licensed clinical nurse specialist and an associate clinical professor at the University of California San Francisco School of Nursing. Ms. Viele has nearly 25 years of experience in oncology supportive care. In this episode, she discusses nursing management of tumor lysis syndro…
 
Adam Carroll, PhD, is chief science officer and co-founder of Amplion, a biotechnology company located in Bend, Oregon. Dr. Carroll completed his PhD in biochemistry at the University of California, San Francisco, and his prior work and interests include advanced drug delivery, biotherapeutic production, and software algorithm development in biomed…
 
Philip McCarthy, MD is the director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York. He has been in oncology practice for more than 20 years. His research interests include patient outcomes after blood and marrow transplantation, blood and marrow stem cell isolation, and preclinical models of bone ma…
 
Rudolph M. Navari, MD is the Director of the Cancer Care Program in Central and South America for the World Health Organization. He has practiced oncology for nearly 30 years. His research interests are focused on supportive care in clinical oncology, development of antiemetics, palliative care, and the doctor-patient relationship in clinical oncol…
 
Judith Paice, PhD, RN is director of the Cancer Pain Program at the Northwestern University Feinberg School of Medicine. She has worked in the field of oncology for more than 30 years. Her research interests are focused on the prevention and management of cancer pain and chemotherapy-induced peripheral neuropathy. She spoke with Oncology Data Advis…
 
Allyson Ocean, MD is an associate professor of medicine at Weill Medical College of Cornell University in New York City. Her main clinical interests are focused on gastrointestinal malignancies, including cancers of the esophagus, stomach, pancreas, colon, and rectum, and her research involves studying the pathways that relate to the growth of thes…
 
Bradley Monk, MD is a gynecologic oncologist and professor at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. His main clinical interests include gynecologic malignancies and quality-of-life aspects of cancer care. He spoke with Oncology Data Advisor about the definition of recurrent ovarian …
 
Laura Griffith, RN, MSN, AOCNS is a licensed clinical nurse specialist in adult hematology/oncology and bone marrow transplant at the University of California San Francisco. She has nearly 15 years of experience in oncology supportive care. Continuing the conversation on sinusoidal obstruction syndrome (SOS) started with Carole Viele, Ms. Griffith …
 
Carol Viele, RN, MS, OCN, CNS is a licensed clinical nurse specialist and an associate clinical professor at the University of California San Francisco School of Nursing. She has nearly 25 years of experience in bone marrow transplantation and oncology supportive care. Ms. Viele spoke with Oncology Data Advisor about why sinusoidal obstruction synd…
 
Louis F. Diehl, MD is a professor of medicine at Duke University School of Medicine with a long-standing interest and involvement in the staging and treatment of hematologic malignancies. He recently served as chairperson of the 2016 Asheville Hematologic Malignancies Symposium where Oncology Data Advisor spoke with him about the evolving standards…
 
Anjali Advani, MD is an associate professor at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Her main clinical interests include myelodysplasia and acute leukemias, with a focus on molecular targeted therapies and novel treatment strategies for acute myeloid leukemia and acute lymphoblastic leukemia (ALL). She …
 
Jeffrey Zonder, MD is a professor of oncology at the Karmonos Cancer Institute in Detroit, Michigan. He has won teaching awards at Wayne State University in 2005 and 2007, is a member of the SWOG Barlogie-Salmon Myeloma Committee, serves as a medical advisor for Amyloidosis Support Groups, Inc, and runs the blog, Amyloid Planet. He spoke with Oncol…
 
John Leonard, MD is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medical College in New York City. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about optimizing therapeutic approaches for mantle cell lymphoma in the context of limited randomized tri…
 
Michael Mauro, MD is the leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center in New York City. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about the implications of generic cancer drugs for clinical decision making, managing highly resistant patients, and expe…
 
Steven Horwitz, MD is an associate professor of medicine at Weill Cornell Medical College and a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. Oncology Data Advisor spoke with Dr. Horwitz at the 2016 Asheville Hematologic Malignancies Symposium about current challenges and new opportunities in the treatment of patien…
 
Jeffrey Lancet, MD is interim chair in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida. In this podcast, he talks with Oncology Data Advisor about challenges facing the contemporary management of acute myeloid leukemia, the importance of well-designed clinical trials, and new therapies on the horizon. Discussion No…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login